ORMP · Oramed Pharmaceuticals Inc

-

Please sign in to comment on ORMP

1 Comment

Admin

4 years, 1 month ago

Oramed Pharmaceuticals Inc is currently in a long term uptrend where the price is trading 57.9% above its 200 day moving average.

From a valuation standpoint, the stock is 93.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 85.6.

Oramed Pharmaceuticals Inc's total revenue sank by 0.0% to $674K since the same quarter in the previous year.

Its net income has dropped by 119.0% to $-6M since the same quarter in the previous year.

Finally, its free cash flow fell by 115.6% to $-6M since the same quarter in the previous year.

Based on the above factors, Oramed Pharmaceuticals Inc gets an overall score of 2/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US68403P2039
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Target Price	3.25
Beta	1.49
Market Cap	95M
Dividend Yield	None

ABOUT

Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

ORMP · Oramed Pharmaceuticals Inc

-

Oramed Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Oramed Pharmaceuticals Inc using a moving average strategy